NASDAQ:OMCL Omnicell (OMCL) Stock Price, News & Analysis $28.69 -1.08 (-3.63%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$28.70 +0.00 (+0.02%) As of 07/11/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Omnicell Stock (NASDAQ:OMCL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Omnicell alerts:Sign Up Key Stats Today's Range$28.68▼$29.4950-Day Range$24.63▼$31.6852-Week Range$22.66▼$55.75Volume255,198 shsAverage Volume563,698 shsMarket Capitalization$1.34 billionP/E Ratio62.37Dividend YieldN/APrice Target$44.83Consensus RatingModerate Buy Company Overview Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas. Read More Omnicell Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreOMCL MarketRank™: Omnicell scored higher than 64% of companies evaluated by MarketBeat, and ranked 311th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingOmnicell has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageOmnicell has only been the subject of 4 research reports in the past 90 days.Read more about Omnicell's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth13.76% Earnings GrowthEarnings for Omnicell are expected to grow by 13.76% in the coming year, from $1.09 to $1.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omnicell is 62.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.84.Price to Earnings Ratio vs. SectorThe P/E ratio of Omnicell is 62.37, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.21.Price to Book Value per Share RatioOmnicell has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Omnicell's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.73% of the float of Omnicell has been sold short.Short Interest Ratio / Days to CoverOmnicell has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Omnicell has recently decreased by 12.20%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOmnicell does not currently pay a dividend.Dividend GrowthOmnicell does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.73% of the float of Omnicell has been sold short.Short Interest Ratio / Days to CoverOmnicell has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Omnicell has recently decreased by 12.20%, indicating that investor sentiment is improving significantly. News and Social Media1.5 / 5News Sentiment0.63 News SentimentOmnicell has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Omnicell this week, compared to 6 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Omnicell insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.52% of the stock of Omnicell is held by insiders.Percentage Held by Institutions97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Omnicell's insider trading history. Receive OMCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter. Email Address OMCL Stock News HeadlinesOmnicell Stock Guidance | NASDAQ:OMCL - BenzingaJuly 12 at 6:40 AM | benzinga.comOmnicell’s Q1 Earnings Call: Our Top 5 Analyst QuestionsJune 27, 2025 | finance.yahoo.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 12 at 2:00 AM | Porter & Company (Ad)3 Cash-Heavy Stocks Facing HeadwindsJune 24, 2025 | finance.yahoo.comQ1 Rundown: Omnicell (NASDAQ:OMCL) Vs Other Healthcare Technology for Providers StocksJune 17, 2025 | msn.comDo Options Traders Know Something About Omnicell Stock We Don't?June 13, 2025 | msn.com1 Cash-Producing Stock with Promising Prospects and 2 to Keep Off Your RadarJune 9, 2025 | msn.comOmnicell CFO Nchacha Etta to Step DownJune 5, 2025 | tipranks.comSee More Headlines OMCL Stock Analysis - Frequently Asked Questions How have OMCL shares performed this year? Omnicell's stock was trading at $44.52 at the start of the year. Since then, OMCL stock has decreased by 35.6% and is now trading at $28.69. How were Omnicell's earnings last quarter? Omnicell, Inc. (NASDAQ:OMCL) issued its quarterly earnings results on Tuesday, May, 6th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.10. The firm's revenue was up 9.5% compared to the same quarter last year. Read the conference call transcript. Does Omnicell have any subsidiaries? Omnicell subsidiaries include MarkeTouch Media LLC, ReCept Pharmacy, FDS Amplicare, 340B Link Business, InPharmics, Ateb Inc., Aesynt, and others. Who are Omnicell's major shareholders? Top institutional investors of Omnicell include Assenagon Asset Management S.A. (0.02%) and Diversified Trust Co (0.02%). Insiders that own company stock include Randall A Lipps, Peter J Kuipers, Mark W Parrish, Scott Peter Seidelmann, Joanne B Bauer and Christine Marie Mellon. View institutional ownership trends. How do I buy shares of Omnicell? Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Omnicell own? Based on aggregate information from My MarketBeat watchlists, some other companies that Omnicell investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/06/2025Today7/12/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryHealth Care Technology Current SymbolNASDAQ:OMCL CIK926326 Webwww.omnicell.com Phone(877) 415-9990Fax847-596-3402Employees3,670Year Founded1992Price Target and Rating Average Price Target for Omnicell$44.83 High Price Target$64.00 Low Price Target$34.00 Potential Upside/Downside+56.3%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.46 Trailing P/E Ratio62.37 Forward P/E Ratio26.32 P/E GrowthN/ANet Income$12.53 million Net Margins1.87% Pretax Margin2.98% Return on Equity4.60% Return on Assets2.56% Debt Debt-to-Equity Ratio0.13 Current Ratio1.38 Quick Ratio1.23 Sales & Book Value Annual Sales$1.11 billion Price / Sales1.21 Cash Flow$2.95 per share Price / Cash Flow9.73 Book Value$26.84 per share Price / Book1.07Miscellaneous Outstanding Shares46,840,000Free Float45,664,000Market Cap$1.34 billion OptionableOptionable Beta0.76 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:OMCL) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredDid you miss out on Trump’s “birthday gift” to Americans?While protestors were rallying against “King Trump,” one trader quietly spotted a 15% weekend move tied to his...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omnicell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omnicell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.